Towards a more representative Alzheimer’s disease clinical trial: Ethnic differences in underlying pathology call for demographic consideration in drug label development

Clinical trials have historically underrepresented racial and ethnic minority groups, often exhibiting sub‐par external validity and representing a population that is exceedingly White and not Hispanic or Latino (H/L). An understanding of the underlying pathology and safety profile of racial and ethnic minority groups is important to interpretation of clinical trial results and the development of accurate drug labels. T3D Therapeutics’ Phase 2 PIONEER Study (evaluating the safety and efficacy of lead candidate drug T3D‐959) provides a unique opportunity to examine safety data in an Alzheimer’s disease (AD) trial with a relatively high percentage of H/L subjects.